AI company Dxcover expands its business into the U.S. market, offering an AI-driven multi-omic cancer detection test for commercial use.
In a significant stride towards commercializing its groundbreaking PANAROMIC cancer detection test, UK-based Dxcover has established its United States headquarters in Nashville, Tennessee. This move places the company at the heart of one of the world's most dynamic healthcare and life sciences hubs.
Dxcover's PANAROMIC technology stands out for its multiomic approach, which integrates infrared spectroscopy with AI-driven spectral analysis to deliver a non-invasive, cost-effective, and high-throughput cancer screening platform, known as Drop. Dry. Detect.™. This innovative technique enables whole-system analysis and early detection of cancer from a single sample, pushing the boundaries of early cancer screening.
The new facilities in Nashville will serve multiple strategic roles. They will facilitate local manufacturing of the infrared spectroscopy platform, foster clinical collaborations and partnerships with biotech and healthcare organizations, and act as a research and development hub to further innovate cancer diagnostics.
Matthew J. Baker, Ph.D., CEO and Co-founder of Dxcover, discussed the use of AI in the PANAROMIC technology in an interview with Med-Tech Insights in December 2024. The new facilities are a testament to the company's commitment to this groundbreaking technology, which has demonstrated proof-of-concept in various forms of cancer, including brain, colorectal, lung, and pancreatic cancers.
Dxcover's current plans include launching brain cancer detection tests in the EU and UK in 2025, with a U.S. launch anticipated by 2027. This U.S. expansion supports the company's mission to make early cancer detection widely accessible and enhance global healthcare equity.
The launch of Dxcover's U.S. headquarters marks a major value-building milestone, as the company embarks on deploying its AI-powered multiomic cancer detection test in the world's largest life sciences market. The company looks forward to collaborating with research institutes, health organizations, and biotech start-ups in Nashville, further accelerating innovation and commercialization in early cancer diagnostics.
[1] Source: Dxcover press release, January 2025 [2] Source: Med-Tech Insights, December 2024 [3] Source: Dxcover investor presentation, December 2024
- Dxcover's cutting-edge PANAROMIC technology, combining digital health, science, and artificial intelligence, is set to revolutionize the early detection of medical-conditions like cancer with its non-invasive and cost-effective approach.
- The new facilities in Nashville, a dynamic hub for healthcare and life sciences, will aid in the local manufacturing of the infrared spectroscopy platform, strengthen clinical collaborations, and serve as a research and development hub for medical-conditions such as cancer diagnostics.
- With the U.S. expansion, Dxcover aims to make early cancer detection widely accessible using technology, and enhance health-and-wellness equity for various medical-conditions including brain, colorectal, lung, and pancreatic cancers, as it targets U.S. launches for brain cancer detection by 2027.
